Cyclophilin A: An Independent Prognostic Factor for Survival in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab and Chemotherapy
Colorectal cancer (CRC) ranks as second most common cause of cancer-related deaths. The CRC management considerably improved in recent years, especially due to biological therapies such as bevacizumab. The lack of predictive or prognostic biomarkers remains one of the major disadvantages of using be...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/16/2/385 |
| _version_ | 1797344402312527872 |
|---|---|
| author | Diana Cornelia Moisuc Daniela Constantinescu Mihai Vasile Marinca Bogdan Gafton Mariana Pavel-Tanasa Petru Cianga |
| author_facet | Diana Cornelia Moisuc Daniela Constantinescu Mihai Vasile Marinca Bogdan Gafton Mariana Pavel-Tanasa Petru Cianga |
| author_sort | Diana Cornelia Moisuc |
| collection | DOAJ |
| description | Colorectal cancer (CRC) ranks as second most common cause of cancer-related deaths. The CRC management considerably improved in recent years, especially due to biological therapies such as bevacizumab. The lack of predictive or prognostic biomarkers remains one of the major disadvantages of using bevacizumab in the CRC management. We performed a prospective study to analyze the prognostic and predictive roles of three potential serum biomarkers (Cyclophilin A (CypA), copeptin and Tie2) investigated by ELISA in 56 patients with metastatic CRC undergoing bevacizumab and chemotherapy between May 2019 and September 2021 at baseline and after one and six months of therapy. We showed that low levels of CypA at baseline and after one month of treatment were associated with better overall survival (OS) (42 versus 24 months, <i>p</i> = 0.029 at baseline; 42 versus 25 months, <i>p</i> = 0.039 after one month). For copeptin and Tie2, Kaplan–Meier curves showed no correlation between these biomarkers and OS or progression-free survival. When adjusting for baseline and post-treatment factors, a multivariate Cox analysis showed that low values of CypA at baseline and after one month of treatment were independent prognostic factors for OS and correlated with a better prognosis in metastatic CRC patients. |
| first_indexed | 2024-03-08T11:01:52Z |
| format | Article |
| id | doaj.art-25dbe9fa7f744f079a725a524b76caaa |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-08T11:01:52Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-25dbe9fa7f744f079a725a524b76caaa2024-01-26T15:37:12ZengMDPI AGCancers2072-66942024-01-0116238510.3390/cancers16020385Cyclophilin A: An Independent Prognostic Factor for Survival in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab and ChemotherapyDiana Cornelia Moisuc0Daniela Constantinescu1Mihai Vasile Marinca2Bogdan Gafton3Mariana Pavel-Tanasa4Petru Cianga5Immunology Department, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, RomaniaImmunology Department, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, RomaniaOncology Department, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, RomaniaOncology Department, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, RomaniaImmunology Department, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, RomaniaImmunology Department, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, RomaniaColorectal cancer (CRC) ranks as second most common cause of cancer-related deaths. The CRC management considerably improved in recent years, especially due to biological therapies such as bevacizumab. The lack of predictive or prognostic biomarkers remains one of the major disadvantages of using bevacizumab in the CRC management. We performed a prospective study to analyze the prognostic and predictive roles of three potential serum biomarkers (Cyclophilin A (CypA), copeptin and Tie2) investigated by ELISA in 56 patients with metastatic CRC undergoing bevacizumab and chemotherapy between May 2019 and September 2021 at baseline and after one and six months of therapy. We showed that low levels of CypA at baseline and after one month of treatment were associated with better overall survival (OS) (42 versus 24 months, <i>p</i> = 0.029 at baseline; 42 versus 25 months, <i>p</i> = 0.039 after one month). For copeptin and Tie2, Kaplan–Meier curves showed no correlation between these biomarkers and OS or progression-free survival. When adjusting for baseline and post-treatment factors, a multivariate Cox analysis showed that low values of CypA at baseline and after one month of treatment were independent prognostic factors for OS and correlated with a better prognosis in metastatic CRC patients.https://www.mdpi.com/2072-6694/16/2/385cyclophilin Aprognostic factorbevacizumabchemotherapymetastatic colorectal cancer |
| spellingShingle | Diana Cornelia Moisuc Daniela Constantinescu Mihai Vasile Marinca Bogdan Gafton Mariana Pavel-Tanasa Petru Cianga Cyclophilin A: An Independent Prognostic Factor for Survival in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab and Chemotherapy Cancers cyclophilin A prognostic factor bevacizumab chemotherapy metastatic colorectal cancer |
| title | Cyclophilin A: An Independent Prognostic Factor for Survival in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab and Chemotherapy |
| title_full | Cyclophilin A: An Independent Prognostic Factor for Survival in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab and Chemotherapy |
| title_fullStr | Cyclophilin A: An Independent Prognostic Factor for Survival in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab and Chemotherapy |
| title_full_unstemmed | Cyclophilin A: An Independent Prognostic Factor for Survival in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab and Chemotherapy |
| title_short | Cyclophilin A: An Independent Prognostic Factor for Survival in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab and Chemotherapy |
| title_sort | cyclophilin a an independent prognostic factor for survival in patients with metastatic colorectal cancer treated with bevacizumab and chemotherapy |
| topic | cyclophilin A prognostic factor bevacizumab chemotherapy metastatic colorectal cancer |
| url | https://www.mdpi.com/2072-6694/16/2/385 |
| work_keys_str_mv | AT dianacorneliamoisuc cyclophilinaanindependentprognosticfactorforsurvivalinpatientswithmetastaticcolorectalcancertreatedwithbevacizumabandchemotherapy AT danielaconstantinescu cyclophilinaanindependentprognosticfactorforsurvivalinpatientswithmetastaticcolorectalcancertreatedwithbevacizumabandchemotherapy AT mihaivasilemarinca cyclophilinaanindependentprognosticfactorforsurvivalinpatientswithmetastaticcolorectalcancertreatedwithbevacizumabandchemotherapy AT bogdangafton cyclophilinaanindependentprognosticfactorforsurvivalinpatientswithmetastaticcolorectalcancertreatedwithbevacizumabandchemotherapy AT marianapaveltanasa cyclophilinaanindependentprognosticfactorforsurvivalinpatientswithmetastaticcolorectalcancertreatedwithbevacizumabandchemotherapy AT petrucianga cyclophilinaanindependentprognosticfactorforsurvivalinpatientswithmetastaticcolorectalcancertreatedwithbevacizumabandchemotherapy |